Revolution Medicines
RVMD
119 hedge funds and large institutions have $2.27B invested in Revolution Medicines in 2020 Q4 according to their latest regulatory filings, with 42 funds opening new positions, 37 increasing their positions, 22 reducing their positions, and 12 closing their positions.
250% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 12
68% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 22
33% more funds holding in top 10
Funds holding in top 10: 9 → 12 (+3)
32% more funds holding
Funds holding: 90 → 119 (+29)
15% more capital invested
Capital invested by funds: $1.98B → $2.27B (+$291M)
0.11% more ownership
Funds ownership: 86.4% → 86.51% (+0.11%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$38.6M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$34.2M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
+$30.8M |
| 4 |
State Street
Boston,
Massachusetts
|
+$28.5M |
| 5 |
BI
BVF Inc
San Francisco,
California
|
+$26.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TGI
TRV GP III
Boston,
Massachusetts
|
-$39.5M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$21.7M |
| 3 |
DM
Deerfield Management
New York
|
-$15.8M |
| 4 |
Franklin Resources
San Mateo,
California
|
-$12.6M |
| 5 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$9.65M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TC
126
Telemus Capital
Southfield,
Michigan
| – | -$489K | -10,750 | Closed |
|
127
SG Americas Securities
New York
| – | -$291K | -8,365 | Closed |
|
|
WCA
128
Windsor Creek Advisors
Bethel,
Vermont
| – | -$233K | -6,700 | Closed |
|
129
US Bancorp
Minneapolis,
Minnesota
| – | -$21K | -600 | Closed |
|
|
MAM
130
Meeder Asset Management
Dublin,
Ohio
| – | -$14K | -425 | Closed |
|
131
Osaic Holdings
Scottsdale,
Arizona
| – | -$5K | -150 | Closed |
|
RVMD Hedge Fund Activity: Q4 2020 in Review
119 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Revolution Medicines (RVMD) for Q4 2020, worth a combined $2.27B — up 15% from $1.98B a quarter earlier.
Buyers outnumbered sellers: 42 funds opened new RVMD positions and 12 closed out — a net gain of 30 holders — while 37 added to existing stakes and 22 trimmed.
The largest buyer was BlackRock, adding an estimated $38.6M. The largest seller was TRV GP III, cutting an estimated $39.5M.
- 119 institutional investors held Revolution Medicines (RVMD) as of Q4 2020, up from 90 in Q3 2020.
- Funds reported $2.27B of Revolution Medicines stock for Q4 2020, up 15% quarter-over-quarter.
- 42 funds opened new Revolution Medicines positions in Q4 2020 and 12 closed out, a net change of +30 holders.
- The largest Revolution Medicines buyer in Q4 2020 was BlackRock, an estimated $38.6M added.
- The largest Revolution Medicines seller in Q4 2020 was TRV GP III, an estimated $39.5M sold.
Based on aggregated 13F filings for Q4 2020.